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To the Editor:
We were interested to read the 
article by Evison et al.1 published in the 
January 2015 issue of Journal of Thoracic 
Oncology. We appreciated the idea of 
proposing a risk stratification model for 
negative lymph nodes by endobronchial 
ultrasound guided transbronchial needle 
aspiration (EBUS-TBNA) in lung cancer 
patients. The proposed model increased 
the negative predictive value of EBUS-
TBNA from 91%2 to approximately 
99%. We believe that this model can help 
to discriminate patients that may directly 
proceed to curative treatment after a neg-
ative EBUS-TBNA. On the basis of this 
model, an EBUS-TBNA negative lymph 
node needs no further evaluation if the 
lymph node maximum standardized 
uptake value (SUVmax) is lower than 4, 
the SUVmax ratio between lymph node 
and primary tumor (LN/T SUVmax) is 
lower than 0.4, and the lymph node has 
homogeneous echogenecity during ultra-
sonographic assessment.1
In the absence of distant metas-
tasis, proper staging of mediastinum is 
of great importance for identification of 
patients who are candidates for radical 
curative therapies. Although positron 
emission tomography/computed tomog-
raphy (PET/CT) can never replace 
pathological staging, it is regarded as 
the most accurate imaging modality 
for nodal  staging. However, there are 
a significant number of false positivity 
(underlying inflammatory processes, 
such as immune reaction because 
of presence of tumor, obstructive 
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We welcome the correspondence 
from Professor Koksal and Dr. Ozmen 
in regard to our manuscript published 
in the Journal of Thoracic Oncology. 
In particular, we welcome the oppor-
tunity to correspond with some of the 
first authors to investigate the potential 
value of the “standardized uptake value 
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pneumonia, anthracosis, or granuloma-
tous inflammation) and false negativity 
(microscopic metastasis beyond spatial 
resolution of PET/CT).
In the literature, there are differ-
ent declared PET positivity criteria for a 
lymph node, but are not well validated.3 
A SUVmax level higher than the medi-
astinal blood pool is associated with 
increased probability of malignancy and 
higher sensitivity, but lower specificity.1,4 
Using a cutoff level as “SUVmax higher 
than 2.5” is sometimes low for predicting 
malignancy because of common inflam-
matory conditions. In the study by Evison 
et al., using a SUVmax value higher than 
4 to indicate PET positivity leads to a 
diagnostic performance as follows: sen-
sitivity, 89.9%; specificity, 89.6%; nega-
tive predictive value, 85.8%; positive 
predictive value 92.6%, and diagnostic 
accuracy 89.8%.1
A LN/T SUVmax ratio was first 
defined by Cerfolio et al. as a univer-
sal predictor of lymph node metastasis 
to eliminate the variation of SUVmax 
among different PET scanners. They 
documented that a ratio of 0.56 or higher 
predicts the node to be malignant with a 
chance of 94%.5 After that study, we pro-
posed a level of 0.2, which is lower than 
the study by Cerfolio et al. This low ratio 
was probably because of our study popu-
lation who were early stage cases directly 
referred to surgical resection. None of 
them have a lymph node larger than 1 cm 
in short axis diameter on CT. Besides, 
we considered a lymph node as positive 
if there was a fluoro-deoxy-D-glucose 
(FDG) uptake higher than the surround-
ing mediastinal tissue. Therefore the 
number of pathologically positive lymph 
nodes was extremely low (%14).4
Evison et al. is the first who sug-
gested a LN/T SUV max ratio of 0.4 
and validated it. We think that using 
such a LN/T SUVmax ratio instead of a 
SUVmax threshold can be important for 
tumors with low FDG activities. A tumor 
with a low FDG activity (for example 
low-grade adenocarcinomas) might have 
a metastatic lymph node with low FDG 
activity. We wonder if Evison et al. real-
ized such cases in their study group espe-
cially in EBUS-TBNA positive cases.
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